NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
3.65
+0.20 (+5.80%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close3.45
Open3.48
Bid0.00 x 0
Ask0.00 x 0
Day's Range3.47 - 3.65
52 Week Range2.25 - 5.00
Volume2,915
Avg. Volume11,004
Market Cap56.154M
Beta-0.76
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.31
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces the appointment of Lewis J.

  • Capital Cube13 days ago

    ETFs with exposure to NovaBay Pharmaceuticals, Inc. : November 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NovaBay Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NBY-US. Comparing the performance and risk of NovaBay Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube15 days ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Johnson & Johnson, Tetraphase Pharmaceuticals, Inc., NanoViricides, Inc. and Sonoma Pharmaceuticals, Inc. (JNJ-US, TTPH-US, NNVC-US and SNOA-US) that have also reported for this period. ... Read more (Read more...)

  • Business Wire29 days ago

    NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.

  • ACCESSWIRElast month

    NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, ...

  • Reuterslast month

    BRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder

    Nov 14 (Reuters) - Jinzi Ham Co Ltd * Says unit signs agreement to buy shares in U.S. Novabay Pharmaceuticals Inc for a combined $27.06 million * Says unit will hold 37.14 percent stake in Novabay Pharmaceuticals ...

  • Business Wirelast month

    NovaBay Pharmaceuticals to Hold Third Quarter 2017 Conference Call on November 14

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report third quarter 2017 financial results after market close on Tuesday, November 14.

  • ACCESSWIRE3 months ago

    Dry Eye Advances from NovaBay and Johnson & Johnson Vision's TearScience

    CEOCFO Magazine Reports on a Recent Roundtable of Top Eye Doctors, Who Highlighted Remarkable Advances in the Treatment of Dry Eye SAN DIEGO, CA / ACCESSWIRE / September 26, 2017 / CEOCFO Magazine , an ...

  • Business Wire3 months ago

    NovaBay Pharmaceuticals Receives Notification of Noncompliance with Additional NYSE American Continued Listing Standards

    NovaBay® Pharmaceuticals, Inc. announces receipt of a letter from NYSE American LLC on September 14, 2017 stating that it is not in compliance with the continued listing standard set forth in Section 1003 of the NYSE American Company Guide requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most ...

  • Capital Cube3 months ago

    ETFs with exposure to NovaBay Pharmaceuticals, Inc. : September 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NovaBay Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NBY-US. Comparing the performance and risk of NovaBay Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
    Capital Cube3 months ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Johnson & Johnson, Cempra, Inc., Oragenics, Inc., Tetraphase Pharmaceuticals, Inc. and Sonoma Pharmaceuticals, Inc. (JNJ-US, CEMP-US, OGEN-US, TTPH-US and SNOA-US) that have also reported ... Read more (Read more...)

  • ACCESSWIRE3 months ago

    Eye Surgeon Says Keep Eyelids Healthy with Avenova from NovaBay

    COLUMBUS, OH / ACCESSWIRE / September 18, 2017 / Alice T. Epitropoulos, MD, FACS , co-founder of The Eye Center of Columbus and eye surgeon at the Cataract & Refraction Center of Ohio , offers women advice ...

  • Business Wire3 months ago

    NovaBay Pharmaceuticals to Present at Rodman & Renshaw 19th Annual Global Investment Conference

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chief Financial Officer Jack McGovern is scheduled to present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12th, 2017, at 2:10 p.m.

  • ACCESSWIRE4 months ago

    NovaBay's Avenova Offers Key Benefits in Glaucoma Care

    Daily Wipes with Avenova for Eyelid Hygiene can Prevent some of the Worrisome Complications of Glaucoma, Reports a Top Ophthalmologist RACINE, WI / ACCESSWIRE / August 14, 2017 / Dr. I. Paul Singh , a ...

  • Business Wire4 months ago

    NovaBay Pharmaceuticals Reports Second Quarter 2017 Financial Results

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and six months ended June 30, 2017 and provides a business update.

  • ACCESSWIRE4 months ago

    Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 10, 2017 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 10, ...

  • Business Wire4 months ago

    NovaBay Pharmaceuticals to Hold 2017 Second Quarter Conference Call on August 10, 2017

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces that it will report 2017 second quarter financial results after market close on Thursday, August 10.

  • Accesswire5 months ago

    Fighting Parasitic Eyelid Mites with Avenova from NovaBay Pharmaceuticals

    Dr. Najafi-Tagol, the Founder of the Eye Institute of Marin, Explains Why Avenova is "a Remarkable Advance in Eye Care" During National Dry Eye Awareness Month SAN RAFAEL, CA / ACCESSWIRE / July ...

  • Accesswire5 months ago

    UPDATE: NovaBay's Avenova Highlighted in National Dry Eye Awareness Month

    The release titled, "NovaBay's Avenova Highlighted in National Dry Eye Awareness Month," issued earlier today by Virgina Eye Consultants, is being re-issued to correct a hyperlink in the first ...

  • Accesswire5 months ago

    NovaBay's Avenova Highlighted in National Dry Eye Awareness Month

    Daily Wipes with a New Eyelid Hygiene Product Can Finally Bring Relief from an Often-Painful Condition, Reports a Top Eye Doctor NORFOLK, VA / ACCESSWIRE / July 10, 2017 / John D. Sheppard, M.D., M.M.Sc ...

  • Business Wire5 months ago

    NovaBay Pharmaceuticals Announces CFO Transition

    NovaBay® Pharmaceuticals, Inc. , a specialty pharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces that Jack McGovern will join the company as Chief Financial Officer as of July 17, 2017.

  • Business Wire6 months ago

    NovaBay Pharmaceuticals Joins the Russell Microcap Index

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that it has joined the Russell Microcap® Index.

  • NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
    Capital Cube6 months ago

    NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017

    Categories: Yahoo FinanceGet free summary analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – KaloBios Pharmaceuticals Inc, Johnson & Johnson, Cempra, Inc., Oragenics, Inc., Tetraphase Pharmaceuticals, Inc., SIGA Technologies Inc and Sonoma Pharmaceuticals, Inc. (KBIO-US, JNJ-US, CEMP-US, OGEN-US, ... Read more (Read more...)

  • Business Wire7 months ago

    NovaBay Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

    NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that management is scheduled to present a corporate overview at the 7th Annual LD Micro Invitational Conference on Tuesday, June 6, 2017, at 2:00 p.m.

  • Business Wire7 months ago

    NovaBay Pharmaceuticals Receives Noncompliance Notice from NYSE MKT

    NovaBay® Pharmaceuticals, Inc. today announced receipt of a letter from NYSE MKT LLC on May 16, 2017, stating that it is not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE MKT Company Guide .